Eficacitatea tratamentului leucemiei acute promielocitare la copii şi adulţi

Gladîş Valentina; Corcimaru Ion; Robu Maria; Chelea Iurie; Oleinicova Elena; Plaschevici Irina; Şaraeva Svetlana

Conţinutul numărului revistei

Articolul precedent

Articolul urmator

1528

Ultima descărcare din IBN:
2023-10-18 14:59

SM ISO690:2012

GLADÎŞ, Valentina, CORCIMARU, Ion, ROBU, Maria, CHELEA, Iurie, OLEINICOVA, Elena, PLASCHEVICI, Irina, ŞARAEVA, Svetlana. Eficacitatea tratamentului leucemiei acute promielocitare la copii şi adulţi . In: Analele Ştiinţifice ale USMF „N. Testemiţanu”, 2013, nr. 3(14), pp. 460-464. ISSN 1857-1719.

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

Analele Ştiinţifice ale USMF „N. Testemiţanu”

Numărul 3(14) / 2013 / ISSN 1857-1719

Eficacitatea tratamentului leucemiei acute promielocitare la copii şi adulţi

Pag. 460-464

Gladîş Valentina, Corcimaru Ion, Robu Maria, Chelea Iurie, Oleinicova Elena, Plaschevici Irina, Şaraeva Svetlana

Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu“

Disponibil în IBN: 23 ianuarie 2014

Descarcă PDF

Rezumat

A fost studiată eficacitatea tratamentului la 91 pacienţi cu leucemia acută promielocitară (LAP) în 5 grupuri de vîrstă: 5-12 ani, 13-18 ani, 19-40 ani, 41-60 ani şi de peste 60 ani. La toţi bolnavii s-a efectuat tratament cu acidul all-trans-retinoid (ATRA) în combinatie cu cicluri de polichimiotepaie „5 2”, „7 3”. A fost constatat ca LAP s-a dezvoltat mai frecvent la persoanele cu vîrsta 19-40 ani. Eficacitatea tratamentului a fost mai înaltă în grupurile de vîrstă 13-18 ani, 19-40 ani şi peste 60 ani ( 80%, 85%, 85,7% respectiv). Recidivele LAP au avut loc mai frecvent la copiii cu vîrsta 5-12 ani (75%) şi pacienţii cu vîrsta de peste 60 ani (66,7%).Vărsta pacienţilor cu LAP de 5-12 ani poate fi considerată ca un factor de prognostic nefavorabil.

Efficacy was studied in 91 patients with acute promyelocytic leukemia (APL) in five age groups: 5-12 years, 13-18 years, 19-40 years, 41-60 years and above 60 years. The treatment with all-trans retinoid acid (ATRA) in combination with cycles polichimioterapie „5 2”, „7 3” was performed in all patients . It was found that LAP has developed more frequently in people aged 19-40. Efficacy of the treatment was higher in age groups 13-18 years, 19-40 years and over 60 years (80%, 85%, 85,7% respectively). Relapses occurred more frequently in children aged 5-12 years (75%) and patients aged over 60 years (66,7%). Age of patients with APL 5-12 years may be considered as an unfavorable prognostic factor.

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-28462</cfResPublId>
<cfResPublDate>2013-05-01</cfResPublDate>
<cfVol>14</cfVol>
<cfIssue>3</cfIssue>
<cfStartPage>460</cfStartPage>
<cfISSN>1857-1719</cfISSN>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/28462</cfURI>
<cfTitle cfLangCode='RO' cfTrans='o'>Eficacitatea tratamentului leucemiei acute promielocitare la copii şi adulţi
</cfTitle>
<cfAbstr cfLangCode='RO' cfTrans='o'>A fost studiată eficacitatea tratamentului la 91 pacienţi cu leucemia acută promielocitară (LAP) în 5 grupuri de vîrstă: 5-12 ani, 13-18 ani, 19-40 ani, 41-60 ani şi de peste 60 ani. La toţi bolnavii s-a efectuat tratament cu acidul all-trans-retinoid (ATRA) în combinatie cu cicluri de polichimiotepaie „5 2”, „7 3”. A fost constatat ca LAP s-a dezvoltat mai frecvent la persoanele cu vîrsta 19-40 ani. Eficacitatea tratamentului a fost mai înaltă în grupurile de vîrstă 13-18 ani, 19-40 ani şi peste 60 ani ( 80%, 85%, 85,7% respectiv). Recidivele LAP au avut loc mai frecvent la copiii cu vîrsta 5-12 ani (75%) şi pacienţii cu vîrsta de peste 60 ani (66,7%).Vărsta pacienţilor cu LAP de 5-12 ani poate fi considerată ca un factor de prognostic nefavorabil.</cfAbstr>
<cfAbstr cfLangCode='EN' cfTrans='o'>Efficacy was studied in 91 patients with acute promyelocytic leukemia (APL) in five age groups: 5-12 years, 13-18 years, 19-40 years, 41-60 years and above 60 years. The treatment with all-trans retinoid acid (ATRA) in combination with cycles polichimioterapie „5 2”, „7 3” was performed in all patients . It was found that LAP has developed more frequently in people aged 19-40. Efficacy of the treatment was higher in age groups 13-18 years, 19-40 years and over 60 years (80%, 85%, 85,7% respectively). Relapses occurred more frequently in children aged 5-12 years (75%) and patients aged over 60 years (66,7%). Age of patients with APL 5-12 years may be considered as an unfavorable prognostic factor.</cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2013-05-01T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2013-05-01T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-11098</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2013-05-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11697</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2013-05-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11551</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2013-05-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-10969</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2013-05-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-11447</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2013-05-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-29369</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2013-05-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-29155</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2013-05-01T24:00:00</cfStartDate>
</cfPers_ResPubl>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-11098</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11098-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2013-05-01T24:00:00</cfStartDate>
<cfFamilyNames>Gladîş</cfFamilyNames>
<cfFirstNames>Valentina</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11697</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11697-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2013-05-01T24:00:00</cfStartDate>
<cfFamilyNames>Корчмару</cfFamilyNames>
<cfFirstNames>Ион</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11551</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11551-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2013-05-01T24:00:00</cfStartDate>
<cfFamilyNames>Robu</cfFamilyNames>
<cfFirstNames>Maria</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-10969</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-10969-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2013-05-01T24:00:00</cfStartDate>
<cfFamilyNames>Chelea</cfFamilyNames>
<cfFirstNames>Iurie</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-11447</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-11447-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2013-05-01T24:00:00</cfStartDate>
<cfFamilyNames>Oleinicova</cfFamilyNames>
<cfFirstNames>Elena</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-29369</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-29369-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2013-05-01T24:00:00</cfStartDate>
<cfFamilyNames>Plaschevici</cfFamilyNames>
<cfFirstNames>Irina</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-29155</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-29155-2</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2013-05-01T24:00:00</cfStartDate>
<cfFamilyNames>Шараева</cfFamilyNames>
<cfFirstNames>С.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
</CERIF>